NCT05017623View on ClinicalTrials.gov

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

YH003

All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY

NCT05017623 - A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter